<!--
title: Observational study of people infected with SARS-Cov-2, treated with amantadine
description: DOI: 10.1007/s43440-020-00168-1
published: true
date: 2022-01-07T22:20:50.729Z
tags: #sarscov2, #covid, #infection, #treatment, #efficiacy, #amantadine, #observational, #studies
editor: ckeditor
dateCreated: 2022-01-07T22:20:48.370Z
-->

<p>Observational Study</p>
<p>Pharmacol Rep</p>
<p>. 2020 Dec;72(6):1538-1541.</p>
<p>doi: 10.1007/s43440-020-00168-1. Epub 2020 Oct 10.</p>
<h1><strong>Observational study of people infected with SARS-Cov-2, treated with amantadine</strong></h1>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Aranda-Abreu+GE&amp;cauthor_id=33040252">Gonzalo Emiliano Aranda-Abreu</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33040252/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Aranda-Mart%C3%ADnez+JD&amp;cauthor_id=33040252">José D Aranda-Martínez</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33040252/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ara%C3%BAjo+R&amp;cauthor_id=33040252">Ramiro Araújo</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33040252/#affiliation-3"><sup>3</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hern%C3%A1ndez-Aguilar+ME&amp;cauthor_id=33040252">María Elena Hernández-Aguilar</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33040252/#affiliation-4"><sup>4</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Herrera-Covarrubias+D&amp;cauthor_id=33040252">Deissy Herrera-Covarrubias</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33040252/#affiliation-4"><sup>4</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rojas-Dur%C3%A1n+F&amp;cauthor_id=33040252">Fausto Rojas-Durán</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33040252/#affiliation-4"><sup>4</sup></a></p>
<p>Affiliations expand</p>
<ul>
  <li>PMID: <strong>33040252</strong></li>
  <li>PMCID: <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7547815/">PMC7547815</a></li>
  <li>DOI: <a href="https://doi.org/10.1007/s43440-020-00168-1">10.1007/s43440-020-00168-1</a></li>
</ul>
<p><strong>Free PMC article</strong></p>
<h2><strong>Abstract</strong></h2>
<p><strong>Background: </strong>We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine.</p>
<p><strong>Methodology: </strong>In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days.</p>
<p><strong>Results: </strong>This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2.</p>
<p><strong>Conclusion: </strong>Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.</p>
<p>&nbsp;</p>
<p>https://pubmed.ncbi.nlm.nih.gov/33040252/</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
